Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Interest & Investment Income (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Interest & Investment Income for 3 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 34.45% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, down 31.0% year-over-year, with the annual reading at $7.5 million for FY2025, 31.0% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.3 million at Inhibrx Biosciences, down from $1.8 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $4.7 million in Q4 2023, with the low at $1.3 million in Q4 2025.
  • Average Interest & Investment Income over 3 years is $2.5 million, with a median of $2.3 million recorded in 2025.
  • Peak annual rise in Interest & Investment Income hit 24.44% in 2024, while the deepest fall reached 57.35% in 2024.
  • Over 3 years, Interest & Investment Income stood at $4.7 million in 2023, then crashed by 57.35% to $2.0 million in 2024, then plummeted by 34.45% to $1.3 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.3 million, $1.8 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.